Monday , June 25 2018
Home / Uncategorized / P&G discontinued manufacture and sale of its cold and flu pill Vicks Action 500 Extra, following the govt ban on 344 fixed dose combinations

P&G discontinued manufacture and sale of its cold and flu pill Vicks Action 500 Extra, following the govt ban on 344 fixed dose combinations

P&G discontinued manufacture and sale of its cold and flu pill Vicks Action 500 Extra, following the govt ban on 344 fixed dose combinations

Hyderabad: Procter and Gamble Hygiene and Healthcare Ltd, the Indian unit of US-based consumer goods company P&G, on Tuesday said it has discontinued manufacture and sale of its cold and flu pill Vicks Action 500 Extra, following the Union government ban on 344 fixed dose combinations, citing risk to human beings.

“Our product Vicks Action 500 Extra has the same fixed dose combination and gets covered under this notification,” said Shailyamanyu Singh Rathod, director, P&G, in a statement on Tuesday.

Vicks Action 500 Extra is a combination of paracetamol, phenylephrine and caffeine and is a popular over-the-counter drug for relieving cold and flu symptoms.

“We would like to reinforce that the health, safety and well-being of our consumers is our number one priority at P&G,” he said.

All Vicks products, including Vicks Action 500 Extra, are backed by research to support their safety, quality and efficacy, said the company statement.

The company has products approved by government regulators in over 60 countries and enjoys an excellent safety record, the statement added.

The Central government on Saturday banned 344 fixed dose combination of drugs based on the recommendation of an expert committee that the said drug is found to have no therapeutic justification.

A fixed dose combination (FDC) drug contains two or more drugs combined in a fixed ratio of doses and available in a single dose.

Shares of P&G declined 1.02% and were trading at Rs.6,066 at 9.35am on the BSE, while the benchmark Sensex was down 0.29% to 24,731.70 points.

Pharmaceutical companies have begun weighing their options to challenge the order. Pfizer Ltd, the Indian unit of US-based Pfizer Inc., on Monday got a stay from Delhi high court against the government order to ban its popular cough syrup Corex.

Last year the government reviewed some 6,200 combination drugs, of which some 15-20% were considered “irrational”, a Reuters report said quoting an unnamed government official in December.

According to analysts, the ban could cost Indian pharmaceutical companies about Rs.3,500-3,800 crore.

(adsbygoogle = window.adsbygoogle || []).push({});

click
here for News

(adsbygoogle = window.adsbygoogle || []).push({});

About admin

Previous Reserve Related News : Poor Families Also Get The Benefit Of The Reserve
Next AHMEDABAD Shikshako mate agatya na tamam form babat Paripatra ane forms

Check Also

[Gujarat Board]: 1 To 5 Gujarat Language Books of New NCERT Syllabus Book Of Gujarat Board in One Click.

Mathematics New NCERT Syllabus Book Of Gujarat Board Gujarat State Education Board has adapted NCERT …

GSSSB Female Staff Nurse Final Answer Key 2018

GSSSB Female Staff Nurse Final Answer Key 2018 GSSSB Female Staff Nurse  Finel Answer Key (Ayurveda …

STD 10 SOCIAL SCIENCE MODEL PAPER 1

STD 10 SOCIAL SCIENCE MODEL PAPER 1 CLICK HERE TO DOWNLOAD